eczema

target reach ladder climb meet win beat competition
Biotech

Apogee data drive hype as threat to Lilly, Sanofi becomes clear

Analysts doubled their peak sales forecast to $5.2 billion in the belief zumilokibart will become the first-line treatment for most eczema patients.
Nick Paul Taylor Mar 23, 2026 9:00am
Completing steps towards success checkmark on cubes symbolizing progress

Nektar eczema asset 'checked all of the boxes' in phase 2

Feb 10, 2026 10:55am
Graphic image of an arrow nailing the bullseye of a target

Evommune's Dupixent-like eczema data drive 75% stock rally

Feb 10, 2026 9:31am
Return To Sender stamp on an envelope

Amgen exits $400M autoimmune pact after running vast program

Jan 30, 2026 8:55am
success failure signposts

Sanofi posts mixed phase 3 data on key eczema prospect

Jan 23, 2026 5:43am
bet poker chips las vegas betting gamble

Apollo $15M bet on IL-18 antibody pays off with ph. 2 eczema win

Sep 16, 2025 9:50am